Cardiovascular Diabetology
Papers 1725
1 page of 173 pages (1,725 results)
Published on 2019in Cardiovascular Diabetology5.95
Aaron Y. Kluger1
Estimated H-index: 1
(Baylor University),
Kristen M. Tecson2
Estimated H-index: 2
(A&M: Texas A&M University)
+ 5 AuthorsPeter A. McCullough81
Estimated H-index: 81
To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and explore the potential determinants for their c...
Published on 2019in Cardiovascular Diabetology5.95
Sebastian Reith14
Estimated H-index: 14
(RWTH Aachen University),
Andrea Milzi1
Estimated H-index: 1
(RWTH Aachen University)
+ 4 AuthorsMathias Burgmaier11
Estimated H-index: 11
(RWTH Aachen University)
Coronary calcification is associated with high risk for cardiovascular events. However, its impact on plaque vulnerability is incompletely understood. In the present study we defined the intrinsic calcification angle (ICA) as the angle externally projected by a vascular calcification and analyzed its role as novel feature of coronary plaque vulnerability in patients with type 2 diabetes. Optical coherence tomography was used to determine ICA in 219 calcifications from 56 patients with stable cor...
Published on Mar 11, 2019in Cardiovascular Diabetology5.95
Guillaume Besch4
Estimated H-index: 4
(UFC: University of Franche-Comté),
S. Pili-Floury10
Estimated H-index: 10
(UFC: University of Franche-Comté)
+ 10 AuthorsFrancois Schiele37
Estimated H-index: 37
(UFC: University of Franche-Comté)
Background Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation.
Published on Dec 1, 2019in Cardiovascular Diabetology5.95
Samuel Seidu9
Estimated H-index: 9
(Leicester General Hospital),
Setor K. Kunutsor26
Estimated H-index: 26
(UoB: University of Bristol)
+ 4 AuthorsKamlesh Khunti64
Estimated H-index: 64
(Leicester General Hospital)
Background The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular outcomes and all-cause mortality events in people with diabetes, we conducted an updated meta-analysis of published randomised controlled trials (RCTs) and a pooled analysis of individual participant data (IPD) from three trials.
Published on Feb 25, 2019in Cardiovascular Diabetology5.95
Lucia La Sala13
Estimated H-index: 13
Simona Mrakic-Sposta21
Estimated H-index: 21
(National Research Council)
+ 9 AuthorsGaia Spinetti26
Estimated H-index: 26
Background Impaired glucose tolerance (IGT) is a risk factor for the development of diabetes and related complications that ensue. Early identification of at-risk individuals might be beneficial to reduce or delay the progression of diabetes and its related complications. Recently, microRNAs emerged as potential biomarkers of diseases. The aim of the present study was to evaluate microRNA-21 as a potential biomarker for the risk of developing diabetes in adults with IGT and to investigate its do...
Published on 2019in Cardiovascular Diabetology5.95
Rui Shi (Sichuan University), Ke Shi5
Estimated H-index: 5
(Sichuan University)
+ 5 AuthorsShan Huang (Sichuan University)
Patients with Diabetes mellitus (DM) are susceptible to coronary artery disease (CAD). However, the impact of DM on plaque progression in the non-stented segments of stent-implanted patients has been rarely reported. This study aimed to evaluate the impact of DM on the prevalence, characteristics and severity of coronary computed tomography angiography (CCTA) verified plaque progression in stented patients. A comparison between diabetic and non-diabetic patients was performed. A total of 98 pati...
Published on Dec 1, 2019in Cardiovascular Diabetology5.95
G. Schernthaner5
Estimated H-index: 5
(Medical University of Vienna),
Avraham Karasik18
Estimated H-index: 18
(Sheba Medical Center)
+ 14 AuthorsBoris N. Mankovsky
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently...
Published on Dec 1, 2019in Cardiovascular Diabetology5.95
Satoshi Ida4
Estimated H-index: 4
Ryutaro Kaneko4
Estimated H-index: 4
+ 1 AuthorsKazuya Murata9
Estimated H-index: 9
Background In patients with diabetes, death and cardiovascular diseases are attributed to classical risk factors such as hypertension, dyslipidemia, and smoking habit, whereas these events are attributed to frailty in the remaining patients. In this meta-analysis, we examined the relationship between frailty and mortality, hospitalization, and cardiovascular diseases in patients with diabetes.
Published on Feb 28, 2019in Cardiovascular Diabetology5.95
Huan Liu (WHU: Wuhan University), Yongnan Lyu (WHU: Wuhan University)+ 4 AuthorsYan Li42
Estimated H-index: 42
(WHU: Wuhan University)
Background There is a mutual interaction between inflammation and endocrine disorders in the development of coronary artery disease (CAD). Growth differentiation factor-15 (GDF-15) is associated with CAD, and the effects of testosterone on CAD as reported in literature have been considered as anti-atherosclerotic. The present study aimed to examine the possible association between serum GDF-15 and testosterone in male CAD patients.
Published on Dec 1, 2019in Cardiovascular Diabetology5.95
Salvatore Carbone14
Estimated H-index: 14
(VCU: Virginia Commonwealth University),
Dave L. Dixon11
Estimated H-index: 11
(VCU: Virginia Commonwealth University)
Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 diabetes mellitus (T2DM). In the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, patients with T2DM and high cardiovascular risk treated with canagliflozin had a significantly lower risk of the composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; hospitalization fo...